Products IVD Testing (COVID-19)
LamPORE COVID-19
A rapid, low-cost, highly scalable test for SARS-CoV-2
LamPORE COVID-19 is a complete and streamlined molecular diagnostic assay for routine detection of SARS-CoV-2, the virus that causes COVID-19. The assay is highly scalable, allowing deployment in both high-throughput, traditional laboratory settings as well as low-throughput laboratories and other locations where testing may be required — addressing the need for rapid and routine screening of large numbers of people.
Benefits
Advantages of LamPORE Test
Rapid and scalable
1 - 480 samples per run; up to XXX samples in 8 hours.
Cost-efficient
Consumable purchase only with minimal training, equipment, or hands-on time required.
Accurate
Targets three highly conserved SARS-CoV-2 genes, reducing inconclusive results and requirement for repeat testing.
Reliable
Distinguish low-quality samples from true negatives using inbuilt control.
Specific
Digital, sequence-based negative/positive result ensures higher specificity than achievable with colorimetric LAMP tests.
Complete, end-to-end workflow
Automatable with optional LIMS integration.
The Lampore Assay
A complete, end-to-end assay
The fully integrated workflow comprises a GridION OND device, with built-in analysis software, and consumables, including flow cells and LamPORE Covid-19 kits. The locked-down workflow allows processing of XXXX samples in 8 hours (or 1–480 samples in 2.5 hours) across up to five flow cells. Each flow cell can be addressed and run independently, offering highly flexible, demand-based testing.
Workflow
LamPORE workflow
The LamPORE COVID-19 assay is performed on extracted RNA from upper respiratory and saliva samples. The assay leverages reverse-transcription coupled to loop-mediated isothermal amplification (RT-LAMP) to amplify three highly conserved genes in SARS-CoV-2 positive samples (E gene, N gene, ORF1a) and a negative control gene (human actin).
Requiring a 30-minute incubation at 65ºC, isothermal amplification is a simple and fast method for amplifying a specific target, with no requirement for specialised equipment.
Following amplification, samples are prepared for analysis using Oxford Nanopore’s rapid sample preparation chemistry. Molecular barcode addition at both the amplification and sample preparation stages enables high multiplexing capacity to be achieved for large numbers of samples.
The prepared samples are loaded onto the GridION OND device and real-time analysis begins. When sequencing reads aligning to the SARS-CoV-2 genome and a control target reach a threshold number per sample, the sample can be classed as positive.
The human actin control should amplify in all correctly collected samples and enables the user to discriminate negative results due to sample collection errors rather than the absence of SARS-CoV-2 infection.
Analysis is performed automatically by the GridION OND device with no requirement for manual intervention or interpretation. Results are provided in visual and LIMS-compatible report formats, with the status of each sample clearly identified.
LamPORE COVID-19 Instructions for Use
View detailed protocol information, including consumable requirements and performance specifications.
DownloadPerformance
Specifications
LamPORE COVID-19 provides reliable and routine detection of SARS-CoV-2 from nasopharyngeal swabs. The assay targets three highly conserved regions of the SARS-CoV-2 genome (N gene; E gene; ORF1a), providing enhanced sensitivity and reducing inconclusive results and requirement for repeat testing.
Assay specifications
Sensitivity | XXX |
Specificity | XXX |
Limit of detection | XXX |
GridION OND device specifications
Size | W 370 mm, H 220 mm, D 365 mm |
Weight | 11 Kg |
On-board analysis | Yes |
LIMS compatible | Yes |
Scalable | Run 1–5 flow cells independently (up to 96 samples per flow cell) |
Subscribe
Get in touch
Talk to us
If you have any questions about our products or services, chat directly with a member of our sales team.
Talk to usBook a sales call
To book a call with one of our sales team, please click below.
Book a callRegulatory status
Product availability varies by country and is subject to local regulatory requirements.
Intended use
FDA-Emergency Use Only
CE-IVD
In development
The LamPORE methodology is highly versatile and Oxford Nanopore is developing a number of product line extensions for potential regulatory submission, including:
- Multiplexing of 1,152 samples per flow cell
- Direct from saliva testing
- Multi-pathogen detection
- Portable analysis on the hand-held MinION Mk1C device
COVID-19 research products
Discover how researchers are using nanopore sequencing to enhance our understanding of SARS-CoV-2 through:
- Rapid whole genome sequencing
- Direct RNA sequencing
- Metagenomic sequencing